The demo reached both of those its Main endpoints, with semaglutide 2.four mg demonstrating statistically significant and superior advancements in liver fibrosis without worsening of steatohepatitis, and also resolution of steatohepatitis without worsening of liver fibrosis in those with MASH as compared to placebo.1Mounjaro may be used as one ther